H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Meridian Bioscience (NASDAQ:VIVO) Inc. on Thursday, setting a price target of $30, which is approximately 28.15% above the present share price of $23.41.
Chen expects Meridian Bioscience Inc. to post earnings per share (EPS) of $0.15 for the first quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Meridian Bioscience, with an average price target of $28.
The analysts price targets range from a high of $30 to a low of $26.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $64.15 million and a net profit of $11.14 million. The company's market cap is $1.01 billion.
According to TipRanks.com, H.C. Wainwright analyst Yi Chen is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 74.7% and a 62.72% success rate.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the following segments: Diagnostics and Life Science. The Diagnostics segment consists testing platforms and technologies such as Isothermal DNA Amplification, Rapid Immunoassay, Enzyme-linked Immunoassay, and Anodic Stripping Voltammetry. The Life Science segment distributes bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.